Qiagen Acquires Australia's Corbett for RT-PCR Platform; Deal Worth up to $135M | GenomeWeb
NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired Corbett Life Science, a privately held life sciences instrumentation firm based in Sydney, Australia, in a transaction worth up to $135 million.
Under the terms of the agreement, Qiagen said it will pay approximately $66 million in cash, $4 million in restricted common stock and milestone payments, and “other contingencies” of up to $65 million over the next four years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.